Barclays analyst Emily Field initiated coverage with a Buy rating on PolyPeptide Group AG (PPGN – Research Report) today and set a price target ...

Barclays (LON:BARC) initiated coverage on PolyPeptide Group AG (SIX:PPGN:SW) stock with an Overweight rating and a price target of CHF 40.00. The firm anticipates a return to positive EBITDA for ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Proteins are fundamental to life. They are involved in virtually every process within our bodies, from catalyzing chemical ...

Incretin-mimetic drugs contribute to dramatic weight loss, but this does not solely mean fat loss. In this article, we ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) recognize the significant, immediate and certain cash value the transaction ...

Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data ...